Children in reviews: Methodological issues in child-relevant evidence syntheses by Cramer, Kristie et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Children in reviews: Methodological issues in child-relevant 
evidence syntheses
Kristie Cramer*1, Natasha Wiebe2, Virginia Moyer3, Lisa Hartling1, 
Katrina Williams4, George Swingler5 and Terry P Klassen1
Address: 1Alberta Research Centre for Child Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada, 
2Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada, 3Center for Population and Evidence Based 
Medicine, University of Texas-Houston Health Sciences Center, Houston, Texas, USA, 4Department of Pediatrics and Child Health, The Children's 
Hospital at Westmead, Westmead, New South Wales, Australia and 5School of Child and Adolescent Health, University of Cape Town, Cape Town, 
South Africa
Email: Kristie Cramer* - kcramer@ualberta.ca; Natasha Wiebe - nwiebe@ualberta.ca; Virginia Moyer - virginia.a.moyer@uth.tmc.edu; 
Lisa Hartling - hartling@ualberta.ca; Katrina Williams - KatrinaW@chw.edu.au; George Swingler - SWINGLER@ich.uct.ac.za; 
Terry P Klassen - terry.klassen@ualberta.ca
* Corresponding author    
Abstract
Background: The delivery of optimal medical care to children is dependent on the availability of
child relevant research. Our objectives were to: i) systematically review and describe how children
are handled in reviews of drug interventions published in the Cochrane Database of Systematic
Reviews (CDSR); and ii) determine when effect sizes for the same drug interventions differ
between children and adults.
Methods: We systematically identified all of the reviews relevant to child health in the CDSR 2002,
Issue 4. Reviews were included if they investigated the efficacy or effectiveness of a drug
intervention for a condition that occurs in both children and adults. Information was extracted on
review characteristics including study methods, results, and conclusions.
Results: From 1496 systematic reviews, 408 (27%) were identified as relevant to both adult and
child health; 52% (213) of these included data from children. No significant differences were found
in effect sizes between adults and children for any of the drug interventions or conditions
investigated. However, all of the comparisons lacked the power to detect a clinically significant
difference and wide confidence intervals suggest important differences cannot be excluded. A large
amount of data was unavailable due to inadequate reporting at the trial and systematic review level.
Conclusion: Overall, the findings of this study indicate there is a paucity of child-relevant and
specific evidence generated from evidence syntheses of drug interventions. The results indicate a
need for a higher standard of reporting for participant populations in studies of drug interventions.
Background
Health care decisions for individual patients are influ-
enced by the availability of evidence that pertains most
directly to the patient. However, health care providers are
often faced with a paucity of evidence for specific patient
groups such as children and youth, and thus must rely on
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evidence of questionable applicability as the basis for
their health care decisions.
In the case of children, where there is a recognized gap in
research evidence [1-4], health care providers frequently
extrapolate evidence derived from adult studies to guide
their decision-making [5]. To illustrate, several European
surveys found 29–72% of the drugs prescribed to children
are unlicensed or off-label [6-8]. In the United States 80%
of the new drugs approved between 1984 and 1989 had
no indication for use in children [9]. As a result, children
may be less likely than adults to receive health care that is
based on research in children.
This is unsettling given that it is widely recognized chil-
dren and adults differ [10] in terms of their physiology
and biology as well as the developmental and disease
processes they experience [11,12]. Children and adults
may also differ with respect to their response to therapies.
For example, selective serotonin reuptake inhibitors have
been found to be effective for treating depression in
adults, whereas the evidence suggests these drugs are asso-
ciated with an increased risk of suicidal behaviour in chil-
dren [13]. Children treated with glucocorticosteroids for
long periods of time have been found to be at risk of
growth retardation, whereas this risk does not exist in
adults [14]. Further, phenobarbital has a sedative effect in
adults but may cause paradoxical hyperactivity in children
[15]. These examples illustrate the potential risks of treat-
ing children without child-specific evidence. Nevertheless
until pediatric research is conducted, health care providers
are faced with a serious dilemma. If they deny children
treatments known to be effective in adults, they may deny
them effective treatments. Alternatively, if they treat chil-
dren and/or youth with untested interventions they may
be using treatments that differ in effect or are even
harmful.
Health care providers increasingly turn to evidence syn-
theses to guide their clinical decisions. Systematic reviews
represent the most rigorous and comprehensive synthesis
of information on a specific clinical question. The
Cochrane Collaboration is an international organization
that promotes rigorous methodological standards in the
preparation and maintenance of systematic reviews and
supports the use of evidence by ensuring systematic
reviews are available through the Cochrane Database of
Systematic Reviews (CDSR). The CDSR presents a sample
of high quality systematic reviews upon which to base
methodological investigations [16]. We sought to system-
atically identify all child-relevant reviews published in the
CDSR and describe whether child specific evidence was
available. We then examined whether adults and children
differed with respect to their response to different
therapies.
Methods
Systematic review identification
One investigator reviewed the titles and abstracts of all
1496 complete systematic reviews published in the CDSR
2002, Issue 4 and identified relevant reviews in which: the
efficacy or effectiveness of a drug intervention was investi-
gated and the condition investigated occurs in both chil-
dren and adults. Reviews of conditions judged by a
pediatrician on our research team (TK) to be rare in chil-
dren were excluded. If there was any uncertainty about the
relevance of a review a pediatrician from our research
team was consulted.
Data extraction
Characteristics of each systematic review were extracted
using a standard data collection form. Information was
extracted on review characteristics such as study inclusion
criteria, number of included trials, results, and author's
conclusions (complete list in Appendix A).
Descriptive analysis
Each systematic review was categorized as "adult", "child",
or "mixed" based on the trials the review authors intended
to include and the trials that were actually included. If the
review authors did not specify the population, the
intended review type was categorized as 'not specified'. If
the ages of the trial participants could not be determined,
the actual review type was categorized as 'uncertain'.
Quantitative data analysis: Effect size differences between 
children and adults
Numerical results were analyzed in Stata 7.0 and S-plus
6.0. The primary outcome for our analysis was the pri-
mary outcome investigated in the review. If the systematic
review authors did not specify a primary outcome, the first
outcome listed by the review authors was used. Effect sizes
(e.g., relative risks and standardized mean differences)
and their corresponding standard errors were calculated
for each trial included in each review using the data as pre-
sented in the review. Adults were defined as 18 years and
older and children were defined as 18 years and younger.
Results were combined separately for each review using a
random effects model [17]. For dichotomous results,
summary relative risks (RR) were calculated separately for
children and adults. Then, ratios of RRs (i.e., child RR
divided by adult RR) were estimated using meta-regres-
sion [18] to summarize the relationship between child
and adult RRs (i.e., to investigate potential effect size dif-
ferences between adults and children). The natural loga-
rithm of the RR responses is regressed on a child indicator
variable; the exponentiated estimated coefficient is the
ratio of RR. For drug interventions intended to prevent an
adverse outcome, a ratio of RRs less than 1 indicates that
children experienced more benefit from the drugBMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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intervention than adults. For drug interventions intended
to bring about a beneficial outcome, a ratio of RRs less
than 1 indicates children experienced less benefit from the
drug intervention than adults. A ratio of RR of 0.75 or 1.33
was considered a "small" but clinically relevant difference
and 0.5 or 2 was considered to be a "moderate" difference.
Ninety-five percent confidence intervals (95% CI) were
calculated for each summary statistic.
For reviews reporting continuous variables, standardized
mean differences (SMD) were calculated separately for
adults and children. Differences of SMDs (child SMD
minus adult SMD) were calculated using meta-regression
to summarize the relationship between child and adult
SMDs (i.e., to investigate potential effect size differences
between adults and children). The SMD responses are
regressed on a child indicator variable; the estimated coef-
ficient is the difference in SMD. A difference in SMDs of ±
0.2 was considered a "small" but clinically relevant differ-
ence [19] and of ± 0.5 was considered to be a "moderate"
difference. Ninety-five percent confidence intervals (95%
CI) were calculated for each summary statistic.
Heterogeneity was quantified for the overall summary
estimate using the I2 statistic [20,21], that indicates the
percent variability due to between-study variability as
opposed to within-study variability. An I2 value greater
than 50% was considered moderately large.
Results
Description of child relevant reviews
Of the 1496 completed reviews in the CDSR, 403 were
considered relevant to child health. Five of the relevant
reviews investigated both treatment and preventive inter-
ventions for the same condition; each of these was
counted as two independent reviews. Therefore, 408
reviews published by 34 different Cochrane Collaborative
Review Groups (list available on request) were identified
and evaluated.
Intended review types
In 16% (67/408) of reviews, the authors intended to only
include adult trials; 11% (45/408) intended to only
include child trials; 38% (153/408) intended to include
both; and 35% (143/408) did not specify age criteria.
Thirty-six percent (24/67) of the adult review authors
defined individuals 14 and older as adults, 43% (29/67)
did not provide a definition for "adult", and the remain-
ing 21% defined adults as 18 and older. Four percent (2/
45) of the child review authors defined children as 19
years old and younger, 9% (4/45) did not provide a defi-
nition for "children", and the remaining 87 % (39/45)
defined children as 18 years old and younger. The major-
ity (89%) of the mixed review authors stated they planned
to include children and adults but they did not define
"children" or "adults". The remaining 11% (16/153)
stated they would include individuals greater than one
month.
Actual review types
Fifty-five percent (37/67) of the intended adult reviews
actually included adult trials; 80% (36/45) of the intended
child reviews actually only included child trials; and 63%
(96/153) of the intended mixed reviews actually included
both adult and child trials and/or mixed trials. The types
of trial participants were could not be determined in 35%
(50/143) of the not specified reviews (Table 1).
Characteristics of the reviews
Table 2 outlines the characteristics of the reviews by
intended review type. In 6% (23/408) of the reviews, no
relevant studies were found. The remaining 94% (385/
408) included a median of 8 (interquartile range (IQR) 4–
15) trials. The number of participants included in each
review could be determined in 91% (352/385) of the
reviews; they included a median of 681 (IQR 210–1670)
participants.
Thirteen percent (52/408) of the review authors planned
to conduct a subgroup analysis based on age. Sixty percent
(31/52) of these conducted the planned subgroup analy-
sis and 3% (1/31) of these found a significant effect size
difference by age. Only 11 of these 52 reviews specified
the age groups they planned to compare: older adults to
younger adults (1), children under 5 to adults and chil-
dren over 5 (1), children and adults to older adults (1),
children less than 12 to adolescents and adults older than
12 (1), children (0–12 years old) to adolescents (12–18)
(2), and adults (18+) to children (<18)(5). None of these
comparisons were significant. One unplanned subgroup
analysis by age found a significant difference but the age
used for the subgroup analysis was not reported.
Quantitative data analysis: Effect size differences between 
children and adults
Only 9% (37/408) of the reviews included enough data to
allow for an investigation of effect size differences
between adults and children. Figure 5 depicts the reasons
that data from the majority of the reviews could not be
used for this investigation. Thirty-seven percent of the
reviews had no comparative data; the remaining 54% of
reviews could not be used because of insufficiencies in the
reporting of participant characteristics from the included
trials.
None of these reviews reported separate child and adult
data collected from the same trial, which is the most likely
to provide valid information as both adults and children
would have been exposed to the same experimental pro-BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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cedures [22]. As a result, our analyses were exclusively
based on between study comparisons where the adults
and children may have been exposed to different experi-
mental procedures [22]. Among the 37 reviews, a median
of two studies (IQR 1 to 5) per review were omitted from
the meta-regression because these studies either only pre-
sented collapsed adult and child data or they did not
define the age ranges of the participants (Figure 5).
Table 1: Intended review type versus actual types of included trials
Intended Review Type
Adult Reviews 
N = 67 (%)
Child Reviews 
N = 45 (%)
Mixed Reviews 
N = 153 (%)
Not specified 
Reviews 
N = 143 (%)
Total 
N = 408 (%)
Actual type of 
included  trials
Adult only 37 (55) 0 (0) 17 (11) 24 (17) 78 (19)
Child only 0 (0) 36 (80) 8 (5) 6 (4) 50 (12)
Mixed 9 (13) 7 (16) 96 (63) 51 (36) 163 (40)
Uncertain 18 (27) 2 (4) 24 (17) 50 (33) 94 (23)
No trials 3 (4) 0 (0) 8 (5) 12 (8) 23 (6)
Table 2: Characteristics of the systematic reviews by intended review type
Intended Review Type
Variable Adult Reviews 
N = 67
Child Reviews 
N = 45
Mixed Reviews
 N = 153
Not Specified 
Reviews 
N = 143
Total 
N = 408
Funding, N (%)
External 26 (39) 23 (51) 67 (44) 89 (62) 205 (50)
Internal 56 (84) 24 (53) 92 (60) 93 (65) 265 (65)
No funding 6 (9) 10 (22) 45 (29) 22 (15) 83 (20)
Languages of studies, N (%)
English only 1 (1) 0 0 3 (2) 4 (1)
English and non-English (no language 
restrictions)
34 (51) 16 (36) 53 (35) 54 (38) 157 (38)
Not specified 32 (48) 29 (64) 100 (65) 86 (22) 247 (61)
Included study designs, N (%)
RCT 47 (70) 30 (67) 91 (60) 82 (57) 250 (61)
CCT 20 (30) 15 (33) 62 (40) 60 (42) 157 (38)
Other 0 0 0 1 (0.7) 1 (0.2)
Median number of included trials, 
Median (Interquartile range)
9 (3–14) 10 (5–13) 8 (3–12) 7 (4–17) 8 (4–15)
Median number of participants, Median 
(Interquartile range)
813 (263–1836) 718 (313–1712) 551 (235–1474) 776 (305–2151) 681 (210–
1670)
Number of reviews where the authors 
planned a subgroup analysis by age, N
21 0 3 0 1 0 5 2
Number of reviews where authors 
conducted a subgroup analysis by age, N
26 2 0 3 3 1
Number of reviews where authors 
found a difference in effect between 
adults and children, N
100 01BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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For the main comparison in each review, 24% (9/37) had
useable data for only one child and one adult trial.
Because at least 3 data points are required, data from these
meta-analyses could not be analyzed using meta-regres-
sion and precision around these estimates is absent from
the meta-metagraphs (Figures 1, 2, 3, 4).
The age definitions of adults and children were not con-
sistent across reviews. A sensitively analysis was therefore
conducted in which children were defined as 14 years and
younger and adults were defined as 14 years and older.
There were mostly negligible differences between the dif-
ferent age cutoff estimates.
When we compared the magnitude of effect between
adults and children, only one (1/37) estimate was signifi-
cant; this favored adults [23]. This estimate was significant
for the 14-year cut off (14 studies, 947 patients) but not
for the 18-year cutoff (8 studies, 1405 patients). In this
review any artemisinin drug was compared to standard
treatment (e.g., quinoline drugs) for severe malaria as
measured by mortality.
Four of the 37 meta-analyses measured therapeutic bene-
fit instead of prevention. To create a consistent definition
for direction in the meta-metagraphs, RR for prevention
instead of therapy was measured for these four meta-anal-
yses. When the inverse was used one of these meta-analy-
ses [24] showed a significant difference between adults
and children for both age cutoffs; the results favored chil-
dren [25]. This meta-analysis compared add-on lamotrig-
ine to placebo in drug resistant partial epilepsy as
measured by treatment success; we measured treatment
failure. However, if the outcome in this meta-analysis is
Meta-metagraph comparing child and adult relative risk summaries Figure 1
Meta-metagraph comparing child and adult relative risk summaries. * I2 for the overall relative risk is greater than 
50%. ** the overall relative risk was statistically significant. † an event in the original data indicated benefit; the data has been 
manipulated so that an event indicates harm.BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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left as a therapeutic outcome (as presented in the review)
the ratio of RRs for both age cutoffs is not significant. Four
studies from this meta-analysis (538 patients) were
included in the 18-year subgroup comparison and ten
studies (797 patients) were included in the 14-year sub-
group comparison. Ten studies (425 patients) were omit-
ted from the 18-year subgroup comparison and nine
studies (403 patients) were omitted from the 14-year sub-
group comparison due to undefined age ranges.
Aside from the two meta-analyses discussed above, a sig-
nificant difference between adult and child responses to
therapy was not found in the majority (35/37) of the
meta-analyses. However, in all but one of the compari-
sons [26] contained "small" effect sizes within the plausi-
ble values of the 95% confidence limits. Of the
comparisons that used the 18-year cut off, 59% (17/29)
had point estimates that were larger than the "small"
effect size cutoff and 28% (8/29) had point estimates that
were larger than the "moderate" effect size cutoff. Of the
comparisons that used the 14-year cut off, 63% (12/19)
had point estimates that were larger than the "small"
effect size cutoff and 11% (2/19) had point estimates that
were larger than the "moderate" effect size cutoff. In addi-
tion, of the meta analyses that included enough data
points to be analyzed using meta-regression (N = 25),
84% (21/25) at the 18 year cut off and 79% (11/14) at the
14 year cut off had 95% confidence intervals that con-
tained "moderate" effect sizes.
Discussion
This study provides support for the speculation there is
too little child health evidence available from systematic
reviews published in the CDSR. Although all 408 of the
reviews evaluated here were on topics relevant to children,
only about half intended  (48%) or actually  (52%)
included data from children. Even when reviews included
evidence generated from children, they frequently did not
Meta-metagraph comparing child and adult relative risk summaries, continued Figure 2
Meta-metagraph comparing child and adult relative risk summaries, continued. * I2 for the overall relative risk is 
greater than 50%. ** the overall relative risk was statistically significant. † an event in the original data indicated benefit; the data 
has been manipulated so that an event indicates harm.BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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distinguish between children and adults in the analysis.
Of the reviews that planned to include both children and
adults (39%) only 20% planned a subgroup analysis by
age. When data were available to investigate effect size dif-
ferences between adults and children, the vast majority of
comparisons lacked the power to detect "small" but clini-
cally important differences.
Of particular interest was the finding that substantial var-
iability occurred among the reviews with respect to how
children, adolescents, and adults were defined. Some of
the reviews defined adults as 14 and older whereas others
defined them as 19 and older. The participants were often
only described as "adults", "children", or "school-aged
children". Furthermore, several reviews did not provide
any information about the ages of the participants in the
included studies. For example, 18% of the mixed reviews
did not report the ages of the participants in any of the
included studies and 55% only reported the ages of the
participants in some of the included studies. Perhaps this
is because ages were not reported at the trial level. We
reviewed the included studies in a random sub-sample of
the reviews (N = 40) and found when age characteristics
were not reported in the review, a median of 72% of the
trial authors also did not report age characteristics in the
trial (Figure 5). Poor reporting decreases the amount of
data available for a quantitative subgroup analysis in evi-
dence reviews and limits the generalizability of results by
health care professionals. The CONSORT statement for
reporting of RCTs delineates appropriate reporting of
Meta-metagraph comparing child and adult relative risk summaries, continued Figure 3
Meta-metagraph comparing child and adult relative risk summaries, continued. * I2 for the overall relative risk is 
greater than 50%. ** the overall relative risk was statistically significant. † an event in the original data indicated benefit; the data 
has been manipulated so that an event indicates harm.BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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baseline demographics [27]. Similarly, for meta-analyses
QUOROM, MOOSE and the Cochrane handbook for sys-
tematic reviews of interventions provide guidelines for
appropriate reporting of study characteristics including a
description of the participant populations [28-30].
Our comparisons lacked the power to detect "small" and
most "moderate" clinically significant differences. Several
factors contribute to this lack of power: 1) too few studies;
2) trial authors did not report age characteristics of the
participants, decreasing the number of useable studies; 3)
systematic review authors did not report age data decreas-
ing the number of useable studies; and 4) segregated adult
and child data was not presented in the mixed trials. Until
there is clear evidence whether there are or are not differ-
ences between adults and children, separate analyses need
to be conducted, particularly where there is biological
plausibility for a difference.
Our study was limited by the available data. Because the
definitions for adult and child varied among the reviews,
standard definitions for child (0–18) and adult (18+)
could not be used consistently to categorize the reviews.
Instead, the categories were based on the review author's
definitions, resulting in less precise categories. In addi-
tion, since we did not review psychosocial and educa-
tional interventions the results of this study cannot be
applied to these interventions. We also did not include
reviews of rare conditions because including reviews of
these conditions (frequently recognized as different in
children and adults) had the potential to bias the results
in favour of our hypothesis. Finally, because we only
reviewed and summarized systematic reviews published
in the CDSR, inferences generated from this study can
only be applied to how children are treated in reviews
published in the CDSR.
Since within-study evidence was not available for our
comparisons, these comparisons are limited by potential
Meta-metagraph comparing child and adult SMD summaries Figure 4
Meta-metagraph comparing child and adult SMD summaries. * I2 for the overall relative risk is greater than 50%. ** 
the overall relative risk was statistically significant. † a greater value in the original data indicated less benefit; the data has been 
manipulated so that a greater value indicates more benefit.BMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
Page 9 of 11
(page number not for citation purposes)
Flow of data loss Figure 5
Flow of data loss.
Trial age characteristics at trial level:
By SR, median 72% (IQR 45-100) of trials
also did not report age characteristics
Reasons for uncertainty 
Trial age characteristics at SR level: 
1) None reported; N=7 (18) 
2) Some reported; N=22 (55) 
3) All reported; N=11 (28), all mixed
Adult-child effect size differences 
could be analysed
N=37 (9) 
Unable to determine if adult-child effect 
size differences could be analysed 
N=137 (34) 
Only included
adult trials 
N=78 (19) 
Only included
child trials 
N=50 (12) 
Included adult and 
child trials (mixed)
N=163 (40)
Unable to determine
ages of trial 
participants
N=94 (23) 
N=60
N=37
SR authors intended to
only include adult data
N=67 (16) 
SR authors intended to
only include child data
N=45 (11)
SR authors intended to
include adult and child data
(mixed)
N=153 (38) 
SR authors did not specify
N=143 (35) 
N=77 N=34
N=49
No included
trials
N=23 (6)
Systematic Reviews (SR) relevant to children
and adults within the Cochrane Database of
Systematic Reviews (Issue 4, 2002) 
N=408 (%) 
Adult-child effect size 
differences could not be 
analysed
N=83 (20) 
Subsample
N=40
Reasons why some trial data omitted
1) Outcome not measured
Median 1 trial (IQR 0-5) 
2) Data summaries not usable
Median 0 trials (IQR 0-2) 
3) Age characteristics not reported 
Median 0 trials (IQR 0-1), 18 yr cutoff
Median 0 trials (IQR 0-1.5), 14 yr cutoff
4) Mixed trials, data not stratified
Median 1 trial (IQR 0-4), 18 yr cutoff
Median 1 trial (IQR 0-2.5), 14 yr cutoffBMC Pediatrics 2005, 5:38 http://www.biomedcentral.com/1471-2431/5/38
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between-study confounders [22]. Factors other than the
one of interest may be responsible for any of the observed
effect size differences, hence these inferences are to be
viewed as preliminary, requiring confirmation [22] by
trial level child-adult comparisons (i.e., within study com-
parisons). A potential solution is found in systematic
reviews that use individual patient data (IPD). IPD adds
more power by controlling for between study
confounders and by enabling more sensitive modelling of
the age-effect relationship [31]. Standard definitions of
"child", "adult", and "adolescent" need to be developed
and used in research studies, although caution is indicated
to avoid misclassification bias from inappropriate age
groupings. Very real biological and physiological differ-
ences may be masked by lumping individuals (e.g., ado-
lescents and adults) into the same category.
In addition to including a checklist item for baseline
demographics or study characteristics, guidelines
developed to improve the quality of reporting studies
such as CONSORT, QUOROM, MOOSE, and the
Cochrane handbook for systematic reviews of interven-
tions need to specifically suggest standards for reporting
participant ages [27-30]. As well, to ensure adequate
reporting, investigators need to be aware of and adhere to
these accepted checklists and guidelines. Researchers
planning to conduct studies that include both adults and
children need to consider and investigate the differences
between adults and children. We recommend that an a
priori subgroup analysis by age be included, particularly
when there is biological plausibility for differences.
Conclusion
Our analysis of systematic reviews did not exclude impor-
tant differences in effect sizes between adults and chil-
dren. Our research supports the need for better reporting
in studies of drug interventions. When combining evi-
dence, researchers need to be aware of the potential differ-
ences between the groups they are combining, especially
when known physiological and biological differences
exist. There is a need to define children, adults, and ado-
lescents and to determine when it is appropriate and nec-
essary to do subgroup analysis by age.
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